Business & Tech

Genzyme to Expand in Framingham; Construct $80 Million Plant

Genzyme held a grand opening for its $330 million manufacturing plant in Framingham in October 2012. The new plant would be located on the same street.

Genzyme, announced today, Oct. 15, it is investing $80 million to build a new downstream processing facility for Fabrazyme(R). 

The new plant, which will be located adjacent to the new Fabrazyme cell culture manufacturing site in Framingham, will significantly expand purification capacity to support anticipated growth in global demand over the coming years.

"As we continue to meet the global demands for Fabrazyme and build inventory, our focus also remains on the future needs of the global Fabry community," said Genzyme President and CEO, David Meeker, M.D. "Following last year's regulatory approvals of our manufacturing facility in Framingham and a new vial filling line at our plant in Waterford, Ireland, we continue to execute on our global manufacturing strategy, enhancing our capabilities across the entire manufacturing process for Fabrazyme."

Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.

Downstream processing, a vital step in biologic production, involves the purification of material harvested from the cell culture manufacturing process. The final product, which is administered as an intravenous (IV) infusion, is formulated and fill-finished in a separate facility in Waterford, Ireland and shipped to multiple distribution centers for labeling, packaging and shipping around the world.

Fabrazyme is approved for treatment of Fabry disease, an inherited condition that is characterized by excessive accumulation of the lipid GL-3 in various organs and tissues, which over time can cause renal, cardiac and cerebrovascular events. As a result, patients with Fabry disease typically have a shortened life span, and children must often cope with significant pain and disability. 

Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.

Fabry disease is an inherited and life threatening disease linked to the X chromosome which affects approximately 5,000 patients in the world.

Genzyme held a grand opening for its $330 million manufacturing plant in Framingham in October 2012. That plant employees about 500 employees. It is unknown how many employees the new plant will have.


Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.

We’ve removed the ability to reply as we work to make improvements. Learn more here